Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrei Braester

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
European Journal of Haematology|July 7, 2019
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chainTamar Tadmor, Andrei Braester, Dally Najib, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Haematologica|July 29, 2021
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaOhad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Viruses|February 26, 2022
Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism RegistryBehnood Bikdeli, David Jiménez, Pablo Demelo-Rodriguez, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
European Journal of Haematology|July 7, 2019
A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chainTamar Tadmor, Andrei Braester, Dally Najib, et al.
Leukemia Research|June 2, 2019
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemiaTamar Tadmor, Ilana Levy, Yair Herishanu, et al.
Haematologica|July 29, 2021
Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemiaOhad Benjamini, Lior Rokach, Gilad Itchaki, et al.
Viruses|February 26, 2022
Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism RegistryBehnood Bikdeli, David Jiménez, Pablo Demelo-Rodriguez, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2015
Higher infection rate after 7- compared with 5-day cycle of azacitidine in patients with higher-risk myelodysplastic syndromeYishai Ofran, Kalman Filanovsky, Anat Gafter-Gvili, et al.
American Journal of Hematology|January 25, 2013
Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter studyDrorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, et al.
Leukemia & Lymphoma|August 18, 2021
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcomeIlana Levy, Avital Lavi, Eran Zimran, et al.
American Journal of Hematology|February 26, 2020
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study groupYair Herishanu, Adir Shaulov, Riva Fineman, et al.
Pageof 5